Drug Trial Radar · NCT03474198
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
675
Actual
Start
Mar 21, 2018
Primary completion
Jan 20, 2022
Study completion Jan 20, 2022
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National University Hospital, Singapore; Singapore Clinical Research Institute
- First posted
- Mar 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current standard management strategy for drug-sensitive pulmonary tuberculosis (TB) is to treat with multiple drugs for 6 months, although patients often fail to adhere to the long treatment, leading to poor clinical outcomes including drug resistance, which is expensive and difficult to treat. The TRUNCATE-TB trial evaluates an alternative strategy (the TRUNCATE-TB Management Strategy) comprising treatment for 2 months (8 weeks, extended to 12 weeks if inadequate clinical response) with a regimen predicted to have enhanced sterilising activity ("boosted regimen") and monitoring closely after treatment cessation. Those who relapse (predicted to be always drug sensitive and likely to occur early) will be retreated with a standard 6 month regimen. The trial is a randomized, open-label, multi-arm, multi-stage (MAMS) trial to test the hypothesis that the TRUNCATE-TB Management Strategy is non-inferior to the standard management strategy in terms of longer-term outcomes (clinical status at 96 weeks). If non-inferiority is demonstrated then the advantages/disadvantages of implementing the strategy will be explored in secondary outcomes (from patient and programme perspective). The trial will evaluate the TRUNCATE-TB Management Strategy with 4 potential boosted regimens (180 per arm, total 900 with the standard TB management strategy arm). The boosted regimens include new drugs (licensed drugs, repurposed from other indications) and optimized doses of standard drugs, selected based on consideration of maximal sterilising effect, absence of drug-drug interactions, as well as safety and tolerability over a period of 2 months
Conditions
- Tuberculosis, Pulmonary
Interventions
RifampicinDrug
10mg/kg
IsoniazidDrug
5mg/kg
PyrazinamideDrug
25mg/kg
EthambutolDrug
15mg/kg
LinezolidDrug
600mg
ClofazimineDrug
200mg
RifapentineDrug
1200mg
LevofloxacinDrug
1000mg
BedaquilineDrug
400mg once daily for 2 weeks then 200mg 3x a week
RifampicinDrug
35mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Unsatisfactory clinical outcome at week 96 after randomisationTime frame: 96 weeks
Locations
18 sites in 6 countries. Site status is shown where the registry gives one.
National Institute of TB and Respiratory Diseases
New Delhi, India
Universitas Padjadjaran
Bandung, Indonesia
Persahbahatan Hospital
Jakarta, Indonesia
Wahidin Sudirohusodo Hospital
Makassar, Indonesia
Saiful Anwar Hospital
Malang, Indonesia
Soetomo General Hospital
Surabaya, Indonesia
Perpetual Succour Hospital
Cebu, Philippines
De La Salle Health Sciences Institute
Manila, Philippines
Lung Center Philippines
Manila, Philippines
Philippines Tuberculosis Society Incorporated (PTSI)
Manila, Philippines
Tropical Disease Foundation
Manila, Philippines
Quezon Institute
Quezon City, Philippines
National University Hospital
Singapore, Singapore
King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Central Chest Institute of Thailand
Nonthaburi, Thailand
Infectious Diseases Institute
Kampala, Uganda
Joint Clinical Research Centre
Kampala, Uganda
Joint Clinical Research Centre
Mbarara, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.